skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders

(2910) Views  (957) Full article downloads

Authors: Ruben A Mesa

Published Date November 2007 Volume 2007:1(2) Pages 129 - 138
DOI: http://dx.doi.org/10.2147/BTT.S

Ruben A Mesa

Division of Hematology, Mayo Clinic, Rochester, MN, USA

Abstract: The chronic myeloproliferative disorders (MPDs) include the spectrum of clonal hematopoietic stem cell disorders whose phenotype derive from the primary cell expanded in a proliferative state. The MPDs (which include polycythemia vera (PV), essential thrombocythemia (ET), chronic eosinophilic leukemia (CEL), primary myelofibrosis (PMF), chronic myelomonocytic leukemia (CMML), and systemic mast cell disease (SMCD)) exclude chronic myeloid leukemia (CML) because of the pathognomic importance of the BCR-ABL translocation for the diagnosis and treatment of this disorder with imatinib mesylate. Empiric use of imatinib mesylate against the spectrum of BCR-ABL negative MPDs has had mixed results. Significant benefits were obtained when empiric use of imatinib in CEL and CMML led to significant clinical benefit and the discovery of the role of rearrangements of the platelet derived growth factor receptor -alpha (PDGFRa-FIP1L1 in CEL and SMCD) and -beta (PDGFRb through TEL-PDGFRb) for CMML). Empiric use of imatinib in PMF has been disappointing, and in PV quite modest. Although next generation Abelson kinase inhibitors such as dasatinib or nilotinib may expand the role for these agents in MPDs, targeted inhibition of the mutant kinase JAK2V617F is more likely to make significant therapeutic gains in the classic MPDs of PV, ET, and PMF.

Keywords: myeloproliferative diseases, essential thrombocythemia, polycythemia vera, myelofibrosis, therapy








Readers of this article also read:

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England
α-L-iduronidase therapy for mucopolysaccharidosis type I
Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
Therapeutic vaccines for malignant brain tumors
Prolonged rupture of membranes in term infants: should all babies be screened?
Distinct expression profiles of Notch-1 protein in human solid tumors: Implications for development of targeted therapeutic monoclonal antibodies
Jet lag syndrome: circadian organization, pathophysiology, and management strategies
Management of traumatic events: influence of emotion-centered coping strategies on the occurrence of dissociation and post-traumatic stress disorder
Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed